Deepali Suri, President of ICON Biotech, has been published in Pharmaceutical Executive. Her article draws on insights from 163 biotech leaders across North America, EMEA and APAC, supported by a supplementary survey o...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
A new chapter for biotech: Confidence returns to the market
In this article from Fierce Biotech, Chris Smyth, President of ICON Biotech outlines reasons for optimism in 2024, as the biotech sector looks to bounce back after several challenging years.
-
Revolutionising Drug Development: Key Takeaways from the ICON Biotech Survey
In this article from The Journal of mHealth, Chris Smyth, President of ICON Biotech, dissects the challenges and opportunities discovered in ICON's recent biotech sector survey. He explores strategies for accelerating the drug development process, emphasising the potential of partnerships to strategically support biotech companies, how organisations are addressing the current funding challenges and the industry’s overall commitment to addressing unmet healthcare needs.
-
Biotech in 2024: Opportunities, trends & challenges
In this video interview with Fierce Biotech, Chris Smyth, President of ICON Biotech, provides insight into the operating environment facing biotechs in 2024.
-
ICON biotech sector survey: Insights and projections shaping the industry
In this article from PM360, Chris Smyth, President of ICON Biotech, summarises the main findings from the biotech sector survey and outlines the key implications for biotech including strategic collaboration, innovation and cost optimisation.
-
Capitalising on collaboration and confidence: Survey insights and expectations for biotech in 2024
This article by Chris Smyth, President, ICON Biotech, provides an overview of the recent ICON biotech sector survey findings, and looks at the trend of biotech companies engaging earlier and more comprehensively with CROs to drive efficiencies and realise the full value of their R&D programs.
-
Optimism returns as biotech optimise R&D
In this article, Brandon Early, SVP Project Delivery, outlines some of the key findings from the ICON biotech sector survey of over 130 decision makers in small, mid-size, large biotech and VC organisations.
-
ICON predicts biotech trial demand will grow despite economic pressures
This article from Clinical Insider outlines ICON’s view that the demand for clinical trial services will increase in 2024, in addition to providing an overview of the results of the recent ICON biotech sector survey, the findings of which suggest that biotech R&D spending is likely to increase.
-
48% of biotechs leaning on Big Pharma as current funding method: ICON survey
This article from Fierce Biotech provides an overview of findings from the ICON 2023 biotech sector survey, which shows that despite cash struggles, 60% of the survey respondents anticipate their R&D spend to rise over the next one to two years.
-
Due diligence and beyond
Dr. Sandra Eagle outlines how due diligence has evolved from a discrete standalone technical assessment, to now being an integrated part of the holistic development continuum of an asset.
-
Optimising biotech trial designs to stretch your cash runway
Brandon Early discusses how optimising trials designs at the earliest stages can help innovative biotech companies to maximise their available capital.
